The first, a study by Lindzen et al. (2021) found that an AREG is significantly abundant in ovarian cancer patient ascites and that treatment with an AREG blocking antibody led to prolonged survival in an immunocompetent in vivo wildtype p53 HGSOC model. Here, TP53 is linked to ovarian carcinoma.